Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen L Hardinger

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Pharmacotherapy|November 28, 2006
Rabbit antithymocyte globulin induction therapy in adult renal transplantationKaren L Hardinger
Clinical Transplants|July 5, 2012
The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejectionKaren L Hardinger, Daniel Murillo
World Journal of Transplantation|January 7, 2014
Novel immunosuppressive agents in kidney transplantationKaren L Hardinger, Daniel C Brennan
World Journal of Transplantation|November 1, 2013
Current state of renal transplant immunosuppression: Present and futureHari Varun Kalluri, Karen L Hardinger
The Annals of Pharmacotherapy|March 19, 2024
Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current ApproachesKaren L Hardinger, Daniel C Brennan
Clinical Transplants|June 24, 2011
Bortezomib as rescue therapy for antibody mediated rejection: a single-center experienceKaren L Hardinger, Kelly Alford, Daniel Murillo
Clinical Transplants|June 8, 2010
Bortezomib for acute humoral rejection in two repeat transplant recipientsKaren L Hardinger, Kelly Alford, Daniel Murillo
International Journal of Nephrology and Renovascular Disease|June 17, 2016
Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapyKaren L Hardinger, Daniel Sunderland, Jennifer A Wiederrich
Clinical Transplantation|April 9, 2008
Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetilKaren L Hardinger, Sudarshan Hebbar, Terry Bloomer, et al.
Pharmacotherapy|October 6, 2004
Current and future immunosuppressive strategies in renal transplantationKaren L Hardinger, Matthew J Koch, Daniel C Brennan
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Pharmacotherapy|November 28, 2006
Rabbit antithymocyte globulin induction therapy in adult renal transplantationKaren L Hardinger
Clinical Transplants|July 5, 2012
The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejectionKaren L Hardinger, Daniel Murillo
World Journal of Transplantation|January 7, 2014
Novel immunosuppressive agents in kidney transplantationKaren L Hardinger, Daniel C Brennan
World Journal of Transplantation|November 1, 2013
Current state of renal transplant immunosuppression: Present and futureHari Varun Kalluri, Karen L Hardinger
The Annals of Pharmacotherapy|March 19, 2024
Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current ApproachesKaren L Hardinger, Daniel C Brennan
Clinical Transplants|June 24, 2011
Bortezomib as rescue therapy for antibody mediated rejection: a single-center experienceKaren L Hardinger, Kelly Alford, Daniel Murillo
Clinical Transplants|June 8, 2010
Bortezomib for acute humoral rejection in two repeat transplant recipientsKaren L Hardinger, Kelly Alford, Daniel Murillo
International Journal of Nephrology and Renovascular Disease|June 17, 2016
Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapyKaren L Hardinger, Daniel Sunderland, Jennifer A Wiederrich
Clinical Transplantation|April 9, 2008
Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetilKaren L Hardinger, Sudarshan Hebbar, Terry Bloomer, et al.
Pharmacotherapy|October 6, 2004
Current and future immunosuppressive strategies in renal transplantationKaren L Hardinger, Matthew J Koch, Daniel C Brennan
Pageof 5